Enanta Pharmaceuticals, which is partnered with AbbVie ($ABBV) on a hot new experimental therapy for hepatitis C, has priced its IPO shares at $14. The Watertown, MA developer--a Fierce 15 company--raised $56 million. The biotech priced its shares at the low end of the range, but Enanta is avoiding the deep discounting that was required for other biotechs to complete their maiden offering. Story